Pharma companies are huge corporations with complex operations to ensure the quality of their products and services. The digital therapeutics (DTx) industry has often looked to pharma as a pool of knowledge and best practice on evidence generation, regulation, sales models, etc. However, DTx solutions are distinct from drugs, they are usually safer, they constantly adapt and change, and the ‘consumption’ of the therapy is different. Do DTx companies need to operate like pharma? Join this peer-to-peer conversation where we will deep dive into the following:
What can DTx companies learn from pharmas' operational models? What would we have if DTx companies operated like pharma corporations?
Pharma companies are often admonished for their long processes and lack of agility. Would it make sense for DTx companies to operate like pharma? Why/Why not?
Does the pharma department structure make sense for DTx companies (i.e. medical, marketing, salesforce, supply chain, compliance, regulatory, market access, etc.)? What are the advantages and disadvantages of pharma’s organizational structure?